Rhythm Pharmaceuticals’ drug setmelanotide, indicated for rare obesity disorders, may have to endure risk-sharing, population discounts and value-based agreements with payers for adoption although pharmaceutical mortgages could be a viable alternative. While private insurers and Medicare likely won’t budge on drug access, the rare nature of the disease and consequent high cost makes that doubtful.
Multiple pricing agreements are driven by the irregularity of the conditions for which setmelanotide is striving for approval, as well as the demanded orphan drug price point of USD 300,000 per year. Read more here.
Go deeper with GlobalData
